Insulin maker Novo Nordisk raises full-year targets

Danish pharmaceuticals group Novo Nordisk, the world's leading insulin maker, said Wednesday it is raising its full-year profit targets after sales of its anti-obesity and diabetics treatments boosted its bottom line in the third quarter.